Clinical Trials Browser

Phase 1/2 × OTHER × aumolertinib × Clear all

NCT06947811 2025-06-04

APEAK

Phase 1/2 Recruiting

EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor